D. Boral Capital Reaffirms “Buy” Rating for CorMedix (NASDAQ:CRMD)
D. Boral Capital reaffirmed their buy rating on shares of CorMedix (NASDAQ:CRMD – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $15.00 target price on the stock. Several other equities analysts also recently weighed in on CRMD. Royal Bank of Canada restated an “outperform” rating […]
D. Boral Capital reaffirmed their buy rating on shares of CorMedix (NASDAQ:CRMD – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $15.00 target price on the stock. Several other equities analysts also recently weighed in on CRMD. Royal Bank of Canada restated an “outperform” rating […]
